Reviewing Abeona Therapeutics Inc. (ABEO)’s and Acorda Therapeutics Inc. (NASDAQ:ACOR)’s results – FinanceMercury

Posted: Published on November 6th, 2019

This post was added by Alex Diaz-Granados

Abeona Therapeutics Inc. (NASDAQ:ABEO) and Acorda Therapeutics Inc. (NASDAQ:ACOR) compete with each other in the Biotechnology sector. We will analyze and compare their analyst recommendations, institutional ownership, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

Table 1 shows the gross revenue, earnings per share and valuation for Abeona Therapeutics Inc. and Acorda Therapeutics Inc.

Profitability

Table 2 provides the return on assets, net margins and return on equity of the two firms.

Volatility and Risk

Abeona Therapeutics Inc. has a 1.84 beta, while its volatility is 84.00%, thus making it more volatile than S&P 500. Acorda Therapeutics Inc.s 10.00% more volatile than S&P 500 which is a result of the 1.1 beta.

Liquidity

Abeona Therapeutics Inc.s Current Ratio is 3.3 while its Quick Ratio is 3.3. On the competitive side is, Acorda Therapeutics Inc. which has a 4.3 Current Ratio and a 4 Quick Ratio. Acorda Therapeutics Inc. is better positioned to pay off short and long-term obligations compared to Abeona Therapeutics Inc.

Analyst Recommendations

Abeona Therapeutics Inc. and Acorda Therapeutics Inc. Ratings and Recommendations are available in the next table.

Abeona Therapeutics Inc. has a 360.07% upside potential and an average target price of $12.33. Competitively Acorda Therapeutics Inc. has an average target price of $8.88, with potential upside of 273.11%. The information presented earlier suggests that Abeona Therapeutics Inc. looks more robust than Acorda Therapeutics Inc. as far as analyst view.

Institutional & Insider Ownership

The shares of both Abeona Therapeutics Inc. and Acorda Therapeutics Inc. are owned by institutional investors at 64.4% and 0% respectively. About 0.3% of Abeona Therapeutics Inc.s share are held by insiders. Competitively, insiders own roughly 1.5% of Acorda Therapeutics Inc.s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

For the past year Acorda Therapeutics Inc. has weaker performance than Abeona Therapeutics Inc.

Summary

Acorda Therapeutics Inc. beats on 7 of the 12 factors Abeona Therapeutics Inc.

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases. The companys lead programs are ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B; and ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A. It is also developing EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); EB-201 for for epidermolysis bullosa (EB); ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; ABO-301, an AAV-based gene therapy for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. In addition, the company is developing plasma-based protein therapy pipeline, including SDF Alpha, an alpha-1 protease inhibitor for inherited COPD using its proprietary salt diafiltration ethanol-free process. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Acorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); Zanaflex capsules and tablets for the management of spasticity; and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops CVT-301 that has completed a Phase III clinical trial for the treatment of OFF periods in Parkinsons disease; CVT-427, which has completed a Phase I clinical trial to treat migraine; Tozadenant that is in Phase III clinical trial for reduction of OFF time in Parkinsons disease; SYN120, which is in Phase II clinical trial to treat Parkinsons disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; Cimaglermin alfa that has completed a Phase I clinical trial in heart failure patients; and Chondroitinase Program that is in research stage for the treatment of spinal cord injury. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; SK Biopharmaceuticals Co., Ltd.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Cambridge Enterprise Limited and King's College London; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Womens Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

More:
Reviewing Abeona Therapeutics Inc. (ABEO)'s and Acorda Therapeutics Inc. (NASDAQ:ACOR)'s results - FinanceMercury

Related Posts
This entry was posted in Spinal Cord Injury Treatment. Bookmark the permalink.

Comments are closed.